WhiB-like proteins: Diversity of structure, function and mechanism
Abstract The WhiB-Like (Wbl) proteins are a large family of iron-sulfur (Fe-S) cluster-
containing transcription factors exclusively found in the phylum Actinobacteria, including the …
containing transcription factors exclusively found in the phylum Actinobacteria, including the …
Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA of Mycobacterium abscessus
Low-level drug resistance in noncanonical pathways can constitute steppingstones toward
acquisition of high-level on-target resistance mutations in the clinic. To capture these …
acquisition of high-level on-target resistance mutations in the clinic. To capture these …
A single upstream mutation of whiB7 underlies amikacin and clarithromycin resistance in Mycobacterium abscessus
N De Boeck, C Villellas, E Crespo-Yuste… - Journal of Applied …, 2024 - academic.oup.com
Aims We aimed to investigate the molecular mechanisms underlying the survival of
Mycobacterium abscessus when faced with antibiotic combination therapy. By conducting …
Mycobacterium abscessus when faced with antibiotic combination therapy. By conducting …
[HTML][HTML] Poor efficacy of the combination of clarithromycin, amikacin, and cefoxitin against Mycobacterium abscessus in the hollow fiber infection model
E Vignaud, S Goutelle… - Annals of …, 2025 - ann-clinmicrob.biomedcentral.com
Mycobacterium abscessus (MABS) causes difficult-to-treat pulmonary and extra-pulmonary
infections. A combination therapy comprising amikacin, cefoxitin, and a macrolide agent is …
infections. A combination therapy comprising amikacin, cefoxitin, and a macrolide agent is …
[HTML][HTML] Etienne Vignaud 1 Sylvain Goutelle 2, 3 Charlotte Genestet 1, 4 Jérôme Guitton 3, 5
S Cohen, C Bourg, A Durand, L Lebouteiller, A Bernard… - assets-eu.researchsquare.com
Background Mycobacterium abscessus (MABS) causes difficult-to-treat pulmonary and extra-
pulmonary infections. A combination therapy comprising amikacin, cefoxitin, and a …
pulmonary infections. A combination therapy comprising amikacin, cefoxitin, and a …